New substituted pyrrolidine-3,4-diol derivatives were prepared from D-(-)-and L-(+)-phenyl glycinol. The influence of the configuration and the substitution of the lateral side chain of these derivatives on the inhibition of 25 commercial glycosidases were determined. (2R,3R,4S)-2-({[(1R)-2-Hydroxy-1-phenylethyl]amino}methyl)pyrrolidine-3,4-diol ((+)-7a) was a potent and selective inhibitor of jack bean R-mannosidase (K i ) 135 nM). However, when evaluated on human tumor cells, 7a, and the reference compound swainsonine, did not efficiently inhibit the growth of glioblastoma cells. Further derivatization of the hydroxyl group with lipophilic groups to increase bioavailability improved their growth inhibitory properties for human glioblastoma and melanoma cells. In particular, the 4-bromobenzoyl derivative 26 demonstrated high efficacy for human tumor cells whereas primary human fibroblasts were less sensitive to 26. Therefore, functionalized pyrrolidines have the potential to inhibit the growth of tumor cells and display selectivity for tumor cells when compared to normal cells.
Introduction
Very few therapeutic options exist for the treatment of human glioblastoma and metastatic melanoma, in part because of their resistance to chemotherapeutic agents. 1 Therefore, new drugs have to be developed that are able to overcome resistance, and such novel approaches may be represented by agents targeting the glycosylation pathways of cancer cells. Aberrant glycosylation of glycoproteins and glycolipids was reported to be one of the molecular changes that accompany malignant transformations. 2 As both catabolic and processing glycosidases are involved in the transformation of normal cells to cancer cells and in tumor cell invasion and migration, 3 it has been proposed that the specific inhibition of R-mannosidases involved in the addition of N-linked carbohydrates to glycoproteins may provide a new anticancer strategy [4] [5] [6] able to overcome resistance to conventional chemotherapeutic agents. Clinical trials have demonstrated that swainsonine, a natural inhibitor of Golgi R-mannosidase II, which contains a 4-amino-4-deoxy-mannofuranoside moiety, 7 decreases the growth of solid tumors and hematological malignancies. 8 In particular, Kino and co-workers were the first to report that the subcutaneous administration of swainsonine completely inhibited the growth and the formation of lung metastases of a sarcoma. 9 Nevertheless, the toxicity observed for this alkaloid as well as the undesired coinhibition of lysosomal fucosidases resulted in the search for new, more selective R-mannosidases inhibitors. Some analogues of swainsonine such as 2 (Chart 1) as well as simpler derivatives have shown interesting inhibitory properties. [10] [11] [12] We previously reported that 3,4-dihydroxy-pyrrolidin-2-yl derivatives such as 3 and 4 are selective and competitive inhibitors of R-mannosidase from the jack bean. 13, 14 Recently, we reported that 2-aminomethyl-5-(hydroxymethyl)pyrrolidine-3,4-diol derivatives of type 4 are competitive inhibitors of R-mannosidases with higher potency than the corresponding diamines with no substituent at the C(5) position of the pyrrolidine ring. 15 However, the potential of these molecules to inhibit tumor cell growth was not evaluted.
Here we report the synthesis and characterization of new derivatives of the diamine 3a where a hydroxymethyl substituent was introduced on the lateral side chain of pyrrolidine and was able to inhibit purified glycosidases at low concentration. The effect of these derivatives on the proliferation of human glioblastoma and melanoma cells, two tumors associated with a highproliferative and invasive potential, multiple resistance toward conventional chemotherapeutic agents, and poor prognosis, and on human fibroblasts as models for nontumoral cells was also determined. Drug resistance may result from the expression by tumor cells of enzyme systems able to reverse the cytostatic or cytotoxic effect of these agents or from the expression of efflux pumps able to extrude these agents out of tumor cells. Therefore novel strategies, which must be able to reverse tumor resistance to chemotherapeutic agents, have to be envisioned to treat these cancers. We have previously shown that molecules unrelated to conventional therapeutic agents, such as the drugs targeting the endothelin 16, 17 and the renin-angiotensin 18 systems, or carbohydrate analogues, 19 may be of some interest. In this context, agents able to modify the glycosylation pathways of tumor cells may be particularly valuable.
Results and Discussion
Synthesis. The fully protected carbaldehyde 5 20 was submitted to a reductive amination procedure in the presence of phenylglycinol derivatives and sodium triacetoxyborohydride for an in situ reduction of the soformed imines (Scheme 1). Acidic treatment of protected derivatives 6 afforded diamines 7a-7d with a 40-74% yield (two steps). The previously reported alcohol 8 21 was oxidized under Swern conditions and treated as above with D-(-)-R-phenylglycinol to provide diamine 10, bearing two hydroxymethyl groups, with a 65% yield (three steps).
Functionalization of the primary alcohol of derivative 7a was also performed in order to investigate the role of this hydroxyl moiety in enzyme recognition. D-(-)-Rphenylglycinol was transformed into diallylamine 11 with an 85% yield, allowing protection of the primary alcohol as simple ethers (benzyl and methyl ethers) with good to quantitative yields. Substituted benzyl ethers were also introduced. Palladium promoted cleavage of the allyl moieties in the presence of 2-mercaptobenzoic acid as an allyl scavenger, 21 followed by a reductive amination procedure with carbaldehyde 5, led to diamines 18 and 19, after quantitative deprotection in acidic medium. Deallylation of the 3-fluorobenzyl ether resulted in a poor yield of the corresponding amine 17, which was then submitted to the same sequence of reductive amination/acidic deprotection to provide the functionalized pyrrolidine 20 in 40% yield.
Further derivatives containing lipophilic esters were prepared in order to determine whether modification of the hydroxyl group would improve efficacy (Scheme 2). Moreover, the introduction of lipophilic aromatic moieties should improve cell membrane penetration. D-(-)-R-Phenylglycinol was protected as a tert-butyl carbamate (21), allowing acylation of the primary alcohol with substituted aromatic acyl chlorides. After acidic treatment, the resulting amines were also engaged in a reductive amination procedure with pyrrolidine carbaldehyde 5 to provide compounds 23-26 after quantitative cleavage of the Boc and acetonide protecting groups. Intermediate 21 was also converted into the corresponding azido derivative which was used to introduce amide groups on the lateral side chain of the pyrrolidine such as the substituted benzamide 29.
Inhibition of Purified Plant Glycosidases. The inhibitory potential of compounds 7a-7d, 10, 18-20, 23-26, and 29 toward 25 commercially available glycosidases 22 was determined and compared with the previously reported pyrrolidine derived inhibitors. The data are summarized in Table 1 . The compounds (at 1 mM concentration) did not inhibit R-L-fucosidases (from bovine epididymis or human placenta), R-and -galactosidases (from coffee beans, Aspergillus niger, Aspergillus orizae, Escherichia coli, or jack bean), R-and -glucosidases (from yeast, rice, Aspergillus niger, rhizopus mold, almond, or Caldocellum saccharolyticum), -mannosidases (from Helix pomatia), -xylosidase (from Aspergillus niger), R-N-acetylgalactosaminidase, and -N-acetylglucosaminidase (from chicken liver) (results not shown). However, R-mannosidases from jack bean and almond were inhibited by these derivatives with a high selectivity. In particular, the D-(-)-R-phenylglycinol-substituted derivative 7a was a potent (K i ) 135 nM, IC 50 ) 700 nM), competitive (as determined on a Lineweaver-Burk plot) inhibitor of jack bean R-mannosidase, a reliable model enzyme for mammalian Golgi R-mannosidases II, 23 but was less potent for almond R-mannosidase. Introduction of an hydroxymethyl group on the lateral side chain of the pyrrolidine ring led to a considerable increase of the inhibitory potential in comparison with the nonsubstituted derivative 3a (IC 50 ) 60 µM for 3a vs IC 50 ) 700 nM for 7a, factor of increase ) 85). Its diastereoisomer 7b was much less active (IC 50 ) 100 µM), demonstrating the influence of the stereochemistry of the lateral side chain of the pyrrolidine for optimal recognition by the enzyme. Introduction of a second aromatic group (7c and 7d) resulted in a significant decrease of the inhibition of both R-mannosidases. The steric hindrance of these derivatives may be too important to allow them to enter the active site of the enzyme.
The free hydroxyl group on the lateral side chain seemed to also be a determinant for inhibition since the introduction of a methyl ether (18) led to a drastic loss of inhibitory activity (77% and 63% inhibition at 1 mM for R-mannosidases from the jack bean and almond, respectively). The benzyl-protected derivative 19 still presented an inhibition constant of 16 µM (IC 50 ) 58 µM) toward R-mannosidase from jack bean (80 times less active than 7a). The ester and amide derivatives 23-26 and 29 were also less active than the parent unprotected compound 7a with average IC 50 values of 60 µM and a competitive type of inhibition. This can be explained by an increase of the steric hindrance as well as the loss of potential hydrogen bonding with the active site of the enzyme. Finally, introduction of a second hydroxymethyl group (compound 10) improved the inhibitory potential on R-mannosidase from almond (IC 50 ) 3.0 µM, K i ) 600 nM) when compared with cally active cells. We observed some growth inhibitory activity of 7a on LN18 and LNZ308 at high concentration (results not shown); however this compound was unstable under biological conditions, and we did not investigate it in more detail. As the hydrophilic character of these molecules may hinder their transport across a cell membrane, we prepared more lipophilic derivatives and evaluated them on the growth of human glioblastoma cells exposed for 24, 48, or 72 h to these molecules. These compounds demonstrated a time-and concentration-dependent inhibition of growth, with 26 being the most rapidly active molecule, producing almost complete inhibition within 24 h. These results are summarized in Table 2 .
Swainsonine, an R-mannosidase inhibitor with promising antitumoral properties, 4,7-9 only inhibited by 20% glioblatoma cell growth at 250 µM and was not active at a lower concentration ( Figure 1A ). Compound 7a, the most active inhibitor for plant R-mannosidases, was not active on human glioblastoma cells. These discrepancies could result from a poor cell membrane permeability and a low uptake of these compounds by glioblastoma cells. Among the lipophilic substituents of the lateral side chain of 7a, the 4-bromobenzoyl ester 26 was the most efficient. The replacement of the bromo by a fluoro (24) , or a bromo (25) , or a fluoro (23) , in position 3 of the aromatic ring resulted in the loss of antiproliferative properties. The use of an amide bond rather than an ester bond to link the bromobenzoyl moiety to the pyrrolidine backbone, resulting in 29, decreased the efficacy. 4-Bromobenzoïc acid or ethyl 4-bromobenzoate, which may result from the hydrolysis of 26 by cell esterases, were without effect on glioblastoma and melanoma cell growth (results not shown) excluding an effect from the aromatic substituent. A dose-response evaluation (300-100 µM) of the antiproliferative effects of 26 and 29 (parts B and C of Figure 1 ) in both glioblastoma cells demonstrated the increased efficacy of 26 when compared to swainsonine or 29. The IC 50 values for 26 and 29 were determined to be 125 and 225 µM in LN 18 and LNZ 308 cells, respectively. These results suggest that cellular esterases, rather than peptidases, are able to release the more hydrophilic derivative 7a with a free terminal alcohol, which was shown to be the most active and selective mannosidases inhibitor of this series of pyrrolidine derivatives.
We then evaluated whether 26 has the potential to diminish cell growth by inhibiting the synthesis of DNA and/or proteins. The evaluation of the incorporation of (Figure 2A ) at slightly lower concentrations and to a higher extent than inhibiting leucine incorporation (protein synthesis) ( Figure 2B ). These results suggest that this molecule acts initially by inhibiting DNA synthesis (93% inhibition at 300 µM in LN18), then the rate of protein synthesis will decrease (82% at 300 µM in LN18), resulting in diminished cell survival. Table 3 summarizes and compares the effects on cell growth (MTT assay) after 24 h of exposure to swainsonine, 7a (the best inhibitor for plant R-mannosidases), and 26 in glioblastoma and melanoma, demonstrating the increased efficiency of 26; however it has to be emphasized that relatively high concentrations (>100 µM) must be applied in order to have complete inhibition a Cells were exposed for 24, 48, or 72 h to 0, 100, 200, or 300 µM of the various synthetic derivatives, then the MTT assay was performed for the last 2 h of incubation. The percent of residual mitochondrial activity was calculated as the ratio of treated to control cells.
of cell growth, suggesting that the bioavailability of this series of molecules may be further optimized.
Therefore, 26 was the most promising derivative of this series in glioblastoma cells. Furthermore, we determined whether this compound was also able to inhibit DNA and protein synthesis and survival in human cancer cells originating from a tumor different from glioblastoma, the melanoma. Exposure of human Me237 and Me275 melanoma cells for 6 h to 26 resulted in a blockade of DNA synthesis ( Figure 3A ) and protein synthesis ( Figure 3B ), and after 24 h, the number of metabolically active, melanoma cells decreased ( Figure  3C ), as determined using the MTT assay.
Finally, we evaluated the sensitivity of human fibroblasts, as models for nontumoral cells to 26 (Figure 4 ). Fibroblasts were less sensitive to this compound than glioblastoma and melanoma cells for the inhibition of DNA synthesis after 6 h of exposure ( Figure 4A ) or survival after 24 h of exposure ( Figure 4B ) suggesting some cell selectivity of 26 between tumoral and nontumoral cells.
Conclusion
In conclusion, a series of functionalized pyrrolidine inhibitors of mannosidases have been prepared and evaluated. The phenylglycinol derivative 7a was shown to be a potent, selective and competitive inhibitor of R-mannosidase from the jack bean (K i ) 135 nM). However, it did not inhibit the growth of human tumor cells. We postulated that its hydrophilic character prevented its internalization by cells. In support of this hypothesis, the more lipophilic derivative 26 inhibited the growth of human glioblastoma and melanoma cells more than the growth of human fibroblasts and more efficiently than swainsonine, a potential antitumoral agent. The presence of lipophilic substituents increased the efficacy making these derivatives able to inhibit DNA and protein synthesis and tumor cell survival. a Cells were exposed for 24 h to either swainsonine, compound 7a, or 26 at 0, 100, 200, or 300 µM, then the MTT assay was performed for the last 2 h of incubation. The percent of growth inhibition was calculated by comparing treated to untreated cells.
Thus the exposure of tumor cells to ester derivatives of prodrugs analogue of 26 would result in two advantages: the hydrolysis of the ester would release molecules more active on mannosidases than the prodrugs, and the hydrophilic character of the active molecules following its intracellular hydrolysis by esterases would prevent its passive diffusion out of the cells. Such a strategy already proved to be efficient for ester derivatives of aminolevulinic acid in the context of photodynamic therapy protocols. 24 Therefore, functionalized pyrrolidines represent promising lead agents able to control the progression of human glioblastoma and melanoma, to inhibit DNA and protein synthesis and tumor cell survival, and to display some selectivity for tumor cells compared to nontumoral cells.
Experimental Section
Chemistry. Commercial reagents (Fluka, Aldrich) were used without purification. Solvents were distilled prior to use: tetrahydrofuran (THF) from Na and benzophenone, MeOH from Mg and I2, and CH2Cl2 from CaH2. The light petroleum ether used refers to the fraction boiling at 40-60°C. Solutions after reactions and extractions were evaporated in a rotatory evaporator under reduced pressure. Liquid/solid flash chromatography (FC): columns of silica gel (0.040-0.63 mm, Merck No. 9385 silica gel 60, 240-400 mesh). Thin-layer chromatography (TLC) for reaction monitoring: Merck silica gel 60F 254 plates; detection by UV light; Pancaldi reagent ((NH4)6MoO4, Ce(SO4)2, H2SO4, H2O) or KMnO4. IR spectra: Perkin-Elmer-1420 spectrometer. 1 H NMR spectra: Bruker-ARX-400 spectrometer (400 MHz); δ (H) in ppm relative to the solvent's residual 1 H signal (CHCl3, δ (H) 7.27; CH3OD, δ (H) 3.34) as internal reference; all 1 H assignments were confirmed by 2D-correlation spectroscopy-45 and 2D-nuclear Overhauser effect spectrometry spectra. 13 C NMR spectra: same instrument as above (101 MHz); δ (C) in ppm relative to solvent's C-signal (CDCl3, δ(C) 77.0; CD3OD, δ(C) 48.5) as internal reference; coupling constants J in hertz. MS: Nermag R-10-10C, chemical ionization (NH3) mode m/z (amu) (% relative base peak (100%)). Electrospray mass spectra were obtained from the Swiss Institute of Technology Mass Spectral Facility. Elemental analyses: Ilse Beetz, D-96301 Kronach, Germany. Analytical high-performance liquid chromatography (HPLC) was performed on a Waters 600 apparatus, equipped with a Waters absorbance detector set at 214 nm and C 4, C8, and C18 Grace Vydac columns. Elution was performed using the following gradient over 30 min, 100% (0.9% TFA in H 2O) to 100% (0.9% TFA in MeCN).
Procedure 1: General Method for the Reductive Aminations. NaBH(OAc)3 (1.4 equiv) was added portionwise to a stirred solution of aldehyde RCHO (0.1-0.3 M) and primary amine R′NH2 (0.1-0.3 M) in 1,2-dichloroethane at 25°C. After the complete disappearance of the reagents (TLC monitoring), the solution was poured into a saturated aqueous solution of NaHCO 3 (5 mL per mmol). The organic layer was collected, and the aqueous layer was extracted with EtOAc (10 mL per mmol, 3 times). The combined organic extracts were dried (MgSO 4). Solvent evaporation in vacuo and flash chromatography on silica gel gave pure diamines. 47 (m, 1H), 4.08 (m, 1H ), 3.94 (m, 1HR), 3.88 (d, 1H),  3.82 (d, 1HR), 3.73 (d, 1H ), 3.28 (m, 1H), 2.51 (m, 2H), 1.45,  1.36, 1.32 (3s, 15 H) . 13 06 (d, 1H), 4.17 (m, 1H), 4.07 (d, 1H), 3.88 (dd, 1H), 3.52 (m,  1H), 3.35 (dd, 1H), 3.23 (dd, 1H), 2.98 (dd, 1H), 2.67 (m, 1H) . (-)-9 ). Dimethylsulfoxide (DMSO) (35 µL, 0.50 mmol, 2.4 equiv) was added to a solution of oxalyl chloride (21 µL, 0.24 mmol, 1.15 equiv) in anhydrous dichloromethane (1.5 mL) and cooled to -78°C. After 20 min, alcohol 8 (72 mg, 0.21 mmol, 1 equiv) in solution in anhydrous dichloromethane (2.5 mL) was added dropwise. After 20 min, triethylamine (144 µL, 1.04 mmol, 5 equiv) was added, and the mixture was warmed to -30°C for 20 min. The mixture was poured into water (5 mL) and extracted with dichloromethane (5 mL, 3 times). The combined organic phases were washed with brine (5 mL), dried over MgSO 4, filtered, and concentrated in vacuo to afford a crude aldehyde. Sodium triacetoxyborohydride (62 mg, 0.29 mmol, 1.4 equiv) was added portionwise to a stirred solution of the crude aldehyde (0.21 mmol, 1 equiv) and d-(-)-R-phenylglycinol (29 mg, 0.21 mmol, 1 equiv) in anhydrous dichloroethane (2 mL). After being stirred at room temperature overnight, the solution was poured into a saturated aqueous solution of NaHCO 3 (5 mL). The organic layer was collected, and the aqueous layer was extracted with CH2Cl2 (5 mL, 3 times). The combined organic extracts were dried (MgSO4). Solvent evaporation in vacuo and flash chromatography on silica gel (EtOAc) afforded (-)-9 (63 mg, 65%, 2 steps). 1 127.8, 127.0, 111.6, 96.8, 82.0, 80.3, 79.5, 66.8, 64.9, 64.1,  61.0, 55.2, 47.8, 28.3, 26.2 2-phenylethanol ((-)-11 ). NaH-CO3 (2.45 g, 29.2 mmol, 2 equiv) and allyl bromide (5.05 mL, 58.3 mmol, 4 equiv) were added to a solution of D-(-)-Rphenylglycinol (2 g, 14.6 mmol, 1 equiv) in THF/DMSO (40 mL/10 mL). A catalytic amount of tetrabutylammonium iodide (1.62 g, 4.38 mmol, 0.3 equiv) was added, and the reaction mixture was stirred at 60°C for 3 h. Water (30 mL) was added after the reaction warmed to room temperature. The reaction mixture was extracted with CH2Cl2 (75 mL, 3 times), dried (MgSO4), filtered, and concentrated in vacuo. Purification by flash chromatography (EtOAc/light petroleum 1:1) afforded (-)-11 as a pale yellow oil (2.70 g, 85%). 1 ((-)-12 ). Diallylamine 11 (169 mg, 0.78 mmol, 1 equiv) was dissolved in anhydrous THF (3 mL), under argon atmosphere, and the temperature was cooled to 0°C. Sodium hydride (41 mg, 0.93 mmol, 1.2 equiv, 55% in oil) was added and the reaction mixture was stirred at 0°C for 10 min. Methyl iodide (86 µL, 0.93 mmol, 1.2 equiv) was added, and the mixture was allowed to warm to room temperature. After 2 h, the resulting mixture was poured into a saturated aqueous solution of NaHCO 3 (5 mL) and the aqueous layer was extracted with EtOAc (5 mL, 3 times). The combined organic extracts were dried (MgSO 4), filtered, and concentrated in vacuo. Flash chromatography on silica gel (EtOAc/light petroleum 1:9) afforded (-)-12 (122 mg, 68%). 1 amine ((-)-13 ). Diallylamine 11 (307 mg, 1.41 mmol, 1 equiv) was dissolved in anhydrous THF (5 mL), under argon atmosphere, and the temperature was cooled to 0°C. Sodium hydride (74 mg, 1.70 mmol, 1.2 equiv, 55% in oil) was added, and the mixture was stirred at 0°C for 10 min. Benzyl bromide (201 µL, 1.70 mmol, 1.2 equiv) was added, and the mixture was allowed to warm to room temperature for 12 h. The resulting mixture was poured into a saturated aqueous solution of NaHCO 3 (10 mL), and the aqueous layer was extracted with EtOAc (15 mL, 3 times). The combined organic extracts were dried (MgSO 4), filtered, and concentrated in vacuo. Flash chromatography on silica gel (EtOAc/light petroleum 1:9) afforded (-)-13 (430 mg, 100%). 1 -3,4-diol ((+)-18) . A mixture of Pd(dba)2 (4.11 × 10 -5 mol) and DPPB (8.22 × 10 -5 mol) in THF (0.5 mL) was stirred at room temperature, under argon atmosphere for 15 min. The so-formed catalyst and 2-mercaptobenzoid acid (2.2 equiv, 0.904 mmol) were added to the solution of 12 (95 mg, 0.411 mmol) in anhydrous THF (3 mL), and the reaction was stirred at 60°C for 12 h. The mixture was poured into a 1 M HCl solution (10 mL) and extracted with EtOAc (10 mL, 2 times). The aqueous layer was treated with 1 M NaOH and extracted with EtOAc (10 mL, 3 times). The combined organic extracts were dried (MgSO4) and concentrated in vacuo to afford 15 (62 mg, 100% crude 
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